| Symbol | QTTB |
|---|---|
| Name | Q32 BIO INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 830 WINTER STREET, WALTHAM, Massachusetts, 02451, United States |
| Telephone | +1 781 999-0232 |
| Fax | — |
| — | |
| Website | https://www.q32bio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001661998 |
| Description | Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Q32 Bio Inc. <b>Filed:</b> 2026-07-06 <b>AccNo:</b> 0001493152-26-032227 <b>Size:</b> 20 KB
Read moreNew Form S-3 - Q32 Bio Inc. <b>Filed:</b> 2026-06-25 <b>AccNo:</b> 0001193125-26-282783 <b>Size:</b> 1 MB
Read moreLAPORTE KATHLEEN 🟢 acquired 9.8K shares (1 derivative) of Q32 Bio Inc. (QTTB) at $12.64 Transaction Date: Jun 12, 2026 | Filing ID: 272701
Read moreIwicki Mark T 🟢 acquired 9.8K shares (1 derivative) of Q32 Bio Inc. (QTTB) at $12.64 Transaction Date: Jun 12, 2026 | Filing ID: 272700
Read moreManke Isaac 🟢 acquired 9.8K shares (1 derivative) of Q32 Bio Inc. (QTTB) at $12.64 Transaction Date: Jun 12, 2026 | Filing ID: 272698
Read moreTZIANABOS ARTHUR 🟢 acquired 9.8K shares (1 derivative) of Q32 Bio Inc. (QTTB) at $12.64 Transaction Date: Jun 12, 2026 | Filing ID: 272697
Read moreGRAYZEL DAVID S. 🟢 acquired 9.8K shares (1 derivative) of Q32 Bio Inc. (QTTB) at $12.64 Transaction Date: Jun 12, 2026 | Filing ID: 272692
Read moreThistle Mary 🟢 acquired 9.8K shares (1 derivative) of Q32 Bio Inc. (QTTB) at $12.64 Transaction Date: Jun 12, 2026 | Filing ID: 272690
Read moreXu Diyong 🟢 acquired 9.8K shares (1 derivative) of Q32 Bio Inc. (QTTB) at $12.64 Transaction Date: Jun 12, 2026 | Filing ID: 272686
Read moreLundberg Sven Ante 🟢 acquired 9.8K shares (1 derivative) of Q32 Bio Inc. (QTTB) at $12.64 Transaction Date: Jun 12, 2026 | Filing ID: 272684
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06018428 | A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of… | Phase2 | Alopecia Areata | Active_Not_Recruiting | 2023-09-12 | 2026-09-01 | ClinicalTrials.gov |
| NCT05509023 | Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe A… | Phase2 | Atopic Dermatitis | Active_Not_Recruiting | 2022-09-30 | 2024-12-01 | ClinicalTrials.gov |
| NCT04485481 | Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers | Phase1 | Safety Issues | Completed | 2020-09-08 | 2022-01-12 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| bempikibart (ADX-914) | Other | Phase PHASE2 | Alopecia Areata | ACTIVE_NOT_RECRUITING | NCT06018428 |
| bempikibart (ADX-914) | Other | Phase PHASE2 | Alopecia Areata | ACTIVE_NOT_RECRUITING | NCT06018428 |
| bempikibart (ADX-914) | Other | Phase PHASE2 | Alopecia Areata | ACTIVE_NOT_RECRUITING | NCT06018428 |
| bempikibart (ADX-914) | Other | Phase PHASE2 | Alopecia Areata | ACTIVE_NOT_RECRUITING | NCT06018428 |
| bempikibart (ADX-914) | Other | Phase PHASE2 | Alopecia Areata | ACTIVE_NOT_RECRUITING | NCT06018428 |
| Placebo | Other | Phase PHASE1 | Safety Issues | COMPLETED | NCT04485481 |
| ADX-914 | Other | Phase PHASE1 | Safety Issues | COMPLETED | NCT04485481 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT05509023 |
| ADX-914 | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT05509023 |
| ADX-097 | Other | Phase PHASE2 | IgA Nephropathy | WITHDRAWN | NCT06419205 |
| bempikibart (ADX-914) | Other | Phase PHASE2 | Alopecia Areata | ACTIVE_NOT_RECRUITING | NCT06018428 |
| ADX-097 | DRUG | Phase PHASE2 | IgA Nephropathy | WITHDRAWN | NCT06419205 |
| bempikibart (ADX-914) | DRUG | Phase PHASE2 | Alopecia Areata | ACTIVE_NOT_RECRUITING | NCT06018428 |
| Placebo | DRUG | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT05509023 |
| ADX-914 | DRUG | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT05509023 |